Serious Flaws in Studies Linking COVID-19 and Air Pollution
Studies have yet to prove this link, say Carleton and McGill University epidemiologists
Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations
COVID-19 Q&A on dealing with pandemic fatigue
“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley
New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk
RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study
Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet
Inappropriate prescriptions sending hospitalized seniors back to the ER
Improving hospital prescribing practices may reduce risk of rehospitalization and death
The World Brain Death Project: New publication offers significant and unprecedented consensus on the question of when brain death occurs
Dr. Sam Shemie offers a reference standard for practices worldwide
Study identifies strategies to reduce breast cancer growth and related skeletal lesions
RI-MUHC team publishes findings in the journal, Bone Research
Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients
Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine